EAM
NKTR icon

Exome Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Exome Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-148,830
Closed -$1.67M – 75
2025
Q1 		$1.52M Buy
148,830
+107,618
+261% +$1.41M 1.35% 36
2024
Q4 		$575K Buy
+41,212
New +$727K 0.43% 52

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Exome Asset Management's NKTR Position: Q2 2025 in Review

Exome Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 148,830 shares — an estimated $1.67M sold.

Exome Asset Management first reported a position in NKTR in Q4 2024 and held it in 2 quarters. The position peaked at $1.52M in Q1 2025. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Exome Asset Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exome Asset Management sold 148,830 Nektar Therapeutics shares in Q2 2025, an estimated $1.67M.
  • Exome Asset Management first reported a position in Nektar Therapeutics in Q4 2024 and held it in 2 quarters.
  • Exome Asset Management's Nektar Therapeutics position peaked at $1.52M in Q1 2025.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Exome Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.